Ilumya Side Effects

Generic name: tildrakizumab

Medically reviewed by Philip Thornton, DipPharm. Last updated on Jan 8, 2023.

Note: This document contains side effect information about tildrakizumab. Some dosage forms listed on this page may not apply to the brand name Ilumya.

Applies to tildrakizumab: subcutaneous solution.

Serious side effects of Ilumya

Along with its needed effects, tildrakizumab (the active ingredient contained in Ilumya) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking tildrakizumab:

More common

Body aches or pain
chills
cough
difficulty in breathing
ear congestion
fever
headache
loss of voice
nasal congestion
runny nose
sneezing
sore throat
unusual tiredness or weakness

Incidence not known

Itching skin
large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or genitals

Other side effects of Ilumya

Some side effects of tildrakizumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

Bleeding, blistering, burning, coldness, discoloration of skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site
diarrhea

Rare

Dizziness
pain in the arms and legs

For Healthcare Professionals

Applies to tildrakizumab: subcutaneous solution.

Hypersensitivity

Frequency not reported: Hypersensitivity, angioedema, urticaria^[Ref]

Immunologic

Very common (10% or more): Infections (e.g., upper respiratory tract infection) (23%)^[Ref]

Local

Common (1% to 10%): Injection site reactions (e.g., injection site urticaria, pruritus, pain, reaction, erythema, inflammation, edema, swelling, bruising, hematoma, hemorrhage)^[Ref]

Respiratory

Very common (10% or more): Upper respiratory tract infections (e.g., nasopharyngitis, upper respiratory tract infection, viral upper respiratory tract infection, pharyngitis) (14%)^[Ref]